F10 and cancer: The HOKUSAI-VTE CANCER trial was an open-label RCT that compared 6 to 12 months of the once-daily oral factor Xa inhibitor, edoxaban, versus dalteparin in symptomatic or incidental VTE in 1050 patients with cancer under active treatment.